前列腺健康指数在前列腺癌早期诊断中的价值  

The Value of Prostate Health Index in Early Diagnosis of Prostate Cancer

作　　者：曹志彬 王元天 杨伟忠 朱开常 黄旭元[2] CAO Zhi-bin;WANG Yuan-tian;YANG Wei-zhong;ZHU Kai-chang;HUANG Xu-yuan(Department of Urology,Central Hospital of Jiading District,Shanghai 201800,China;Department of Urology,Renji Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200001,China)

机构地区：[1]上海市嘉定区中心医院泌尿外科,上海201800 [2]上海交通大学医学院附属仁济医院泌尿外科,上海200001

出　　处：《医学信息》2018年第23期29-31,40,共4页Journal of Medical Information

基　　金：嘉定区卫生系统科研项目(编号:KYXM2017-KY-04)

摘　　要：PSA是目前PCa诊断应用最广泛的指标,但由于其敏感性和特异性欠佳,还是造成较多患者接受不必要的前列腺穿刺活检。PHI与传统PSA相比,具有更高的AUC;2012年美国食品和药物管理局批准了PHI用于PSA处于4～10 ng/ml,首次前列腺穿刺活检前的评估,明显提高了前列腺癌检出率。本文就PHI在前列腺穿刺患者的选择和其在高危前列腺癌判断中的价值做一综述。PSA is currently the most widely used indicator for PCa diagnosis,but due to its poor sensitivity and specificity,more patients receive unnecessary prostate biopsy.PHI has a higher AUC than traditional PSA.In2012,the food and drug administration of the United States approved the application of PHI in the assessment of PSA between4-10ng/ml before the first prostate biopsy,significantly increasing the detection rate of prostate cancer.This paper reviews the selection of PHI in patients with prostate puncture and its value in the diagnosis of high-risk prostate cancer.

关 键 词：前列腺癌 前列腺健康指数 前列腺特异性抗原 前列腺特异性抗原前体 

分 类 号：R737.25[医药卫生—肿瘤]